European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma.
bridging
downstaging
hepatocellular carcinoma
immunotherapy
liver transplantation
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
06
2023
accepted:
22
08
2023
medline:
31
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients within transplant criteria and to avoid them from dropping out of the waiting list while awaiting a liver transplant. Moreover, immunotherapy might have great potential to support downstaging and bridging therapies. To address the contemporary status of downstaging, bridging, and immunotherapy in liver transplantation for HCC, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in the treatment of HCC to review literature and to develop guidelines pertaining to this cause that were subsequently discussed and voted during the Transplant Learning Journey (TLJ) 3.0 Consensus Conference that took place in person in Prague. The findings and recommendations of the working group on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma are presented in this article.
Identifiants
pubmed: 37779513
doi: 10.3389/ti.2023.11648
pii: 11648
pmc: PMC10533675
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11648Informations de copyright
Copyright © 2023 Claasen, Sneiders, Rakké, Adam, Bhoori, Cillo, Fondevila, Reig, Sapisochin, Tabrizian and Toso.
Déclaration de conflit d'intérêts
GS discloses consultancy for AstraZeneca, Roche, Novartis, Evidera and Integra. GS has received financial compensation for talks for Roche, AstraZeneca, Chiesi, and Integra. GS has received a grant from Roche. PT discloses consultancy for/receipt of honorarium from Bayer, Boston Scientific, and Aztrazeneca. MR discloses consultancy/advisory role for AstraZeneca, Bayer, BMS, Eli Lilly, Geneos, Ipsen, Merck, Roche, Universal DX, and Boston. MR has received funding from ISCIII and CIBER. MR has given talks for AstraZeneca, Bayer, BMS, Eli Lilly, Gilead, and Roche. MR’s institution has received grant research support from Bayer and Ipsen, and educational support from Astrazeneca, Bayer, Roche, Eisai, Ipsen, Lilly, and Terumo. UC discloses Astellas (Travel Grants & Advisory Board), Eisai (Advisory Board), MSD (Advisory Board), Novartis (Consultant, Travel Grants & Advisory Board), Pfizer (Travel Grants), Sandoz (Advisory Board), Sanofi (Consultant), Springer Healthcare (Copyright & Advisory Board), and J&J (Consultant, Travel Grants). SB discloses talks and has an advisory role for AstraZeneca, Ipsen, MSD, Roche, Eisai, Terumo and Boston Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Adv Ther. 2008 Aug;25(8):787-94
pubmed: 18670743
Liver Int. 2015 Jun;35(6):1715-21
pubmed: 25443863
Ann Surg. 2015 Sep;262(3):536-45; discussion 543-5
pubmed: 26258323
Am J Transplant. 2020 Mar;20(3):879-883
pubmed: 31550417
BMC Cancer. 2022 Mar 14;22(1):270
pubmed: 35287627
J Gastrointest Oncol. 2019 Jun;10(3):562-571
pubmed: 31183208
Liver Transpl. 2021 Dec;27(12):1758-1766
pubmed: 34355489
Cardiovasc Intervent Radiol. 2017 Mar;40(3):410-420
pubmed: 27900445
Cancer Med. 2017 Jan;6(1):26-35
pubmed: 27860456
J Clin Oncol. 2016 Jun 10;34(17):2046-53
pubmed: 26834067
J Immunother Cancer. 2022 Nov;10(11):
pubmed: 36450386
Liver Transpl. 2019 Jul;25(7):1023-1033
pubmed: 31087772
Int J Cancer. 2014 Jan 15;134(2):342-51
pubmed: 23825037
Transplantation. 2021 Dec 1;105(12):e398-e400
pubmed: 34284418
Hepatology. 2001 Jun;33(6):1394-403
pubmed: 11391528
J Vasc Interv Radiol. 2020 Nov;31(11):1729-1738.e1
pubmed: 33012649
Diagn Interv Imaging. 2020 Feb;101(2):101-110
pubmed: 31302075
Gastroenterology. 2005 Jul;129(1):122-30
pubmed: 16012942
Transplantation. 2004 Dec 27;78(12):1780-6
pubmed: 15614151
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Hepatology. 2020 Oct;72(4):1488-1490
pubmed: 32171041
Exp Clin Transplant. 2017 Mar;15(Suppl 2):7-11
pubmed: 28301992
J Hepatol. 2017 Jun;66(6):1114-1117
pubmed: 28284917
Cardiovasc Intervent Radiol. 2015 Apr;38(2):352-60
pubmed: 25373796
Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5
pubmed: 22750200
J Hepatol. 2015 Jul;63(1):83-92
pubmed: 25646884
Transpl Immunol. 2021 Jun;66:101386
pubmed: 33744409
Transpl Int. 2018 Mar 23;:
pubmed: 29572974
Eur J Surg Oncol. 2022 Jan;48(1):121-132
pubmed: 34456082
Transplantation. 2016 Nov;100(11):2391-2397
pubmed: 27780187
J Cancer Res Clin Oncol. 2022 Jan;148(1):245-253
pubmed: 34117916
Cardiovasc Intervent Radiol. 2018 Jan;41(1):112-119
pubmed: 28819771
J Hepatol. 2014 Dec;61(6):1304-11
pubmed: 25064436
Gastroenterology. 2021 Nov;161(5):1502-1512
pubmed: 34331914
Clin J Gastroenterol. 2021 Dec;14(6):1718-1724
pubmed: 34643885
JHEP Rep. 2021 Jul 13;3(5):100331
pubmed: 34485882
Nat Cancer. 2021 Sep;2(9):891-903
pubmed: 34796337
Hepatology. 2022 Oct;76(4):1203-1218
pubmed: 35765265
Radiology. 2017 Mar;282(3):869-879
pubmed: 27673508
Radiology. 2003 Jul;228(1):235-40
pubmed: 12759473
Surg Endosc. 2014 Dec;28(12):3429-34
pubmed: 24935203
J Vasc Interv Radiol. 2020 Jan;31(1):25-34
pubmed: 31422022
PLoS One. 2016 Dec 22;11(12):e0168798
pubmed: 28006010
Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3
pubmed: 9409568
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Br J Cancer. 2013 Apr 2;108(6):1252-9
pubmed: 23449352
J Am Coll Surg. 2017 Apr;224(4):610-621
pubmed: 28069527
Front Immunol. 2021 Jul 19;12:653437
pubmed: 34349755
Cancer. 2004 Jan 15;100(2):376-82
pubmed: 14716774
Clin Gastroenterol Hepatol. 2018 Jun;16(6):955-964
pubmed: 29175528
Radiology. 1995 Dec;197(3):812-8
pubmed: 7480761
Hepatology. 2021 Nov;74(5):2580-2594
pubmed: 34091914
JAMA Surg. 2022 Sep 1;157(9):779-788
pubmed: 35857294
Eur Surg. 2017;49(5):236-243
pubmed: 29104589
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101851
pubmed: 34923180
Heliyon. 2020 May 12;6(5):e03882
pubmed: 32426535
Lancet Oncol. 2020 Jul;21(7):947-956
pubmed: 32615109
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):477-482
pubmed: 27084661
Cancers (Basel). 2022 Jun 03;14(11):
pubmed: 35681757
Hepatology. 2020 Mar;71(3):943-954
pubmed: 31344273
Am J Transplant. 2022 Jun;22(6):1699-1704
pubmed: 35080128
HPB (Oxford). 2020 Aug;22(8):1121-1127
pubmed: 32044268
Radiol Med. 2014 May;119(5):298-308
pubmed: 24277510
Cancer. 2010 Dec 1;116(23):5452-60
pubmed: 20672352
Hepatology. 2018 Jan;67(1):381-400
pubmed: 28859222
Transplantation. 2020 Nov;104(11):2334-2345
pubmed: 32032291
J Hepatol. 2017 Jul;67(1):92-99
pubmed: 28257902
Transpl Int. 2020 May;33(5):567-575
pubmed: 31994238
Ann Hepatobiliary Pancreat Surg. 2018 Feb;22(1):27-35
pubmed: 29536053
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Yonsei Med J. 2021 Jan;62(1):29-40
pubmed: 33381932
Ann Transplant. 2013 Jun 10;18:273-84
pubmed: 23792531
Hepatology. 2015 May;61(5):1579-90
pubmed: 25284802
J Hepatol. 2017 Mar;66(3):552-559
pubmed: 27899297
Cancers (Basel). 2020 Dec 16;12(12):
pubmed: 33339274
J Cancer Res Clin Oncol. 2020 Jul;146(7):1819-1827
pubmed: 32356179
Medicine (Baltimore). 2022 Feb 25;101(8):e28803
pubmed: 35212274
Hepatology. 1997 Nov;26(5):1156-61
pubmed: 9362356
Radiology. 2014 Feb;270(2):607-20
pubmed: 24126369
Int Immunopharmacol. 2016 Nov;40:436-442
pubmed: 27716591
Cardiovasc Intervent Radiol. 2019 Feb;42(2):239-249
pubmed: 30488303
J Hepatocell Carcinoma. 2022 Mar 31;9:265-272
pubmed: 35388358
Lancet Gastroenterol Hepatol. 2018 May;3(5):317-325
pubmed: 29503247
Cardiovasc Intervent Radiol. 2010 Jun;33(3):541-51
pubmed: 19937027
J Immunother. 2013 Jun;36(5):287-93
pubmed: 23719239
J Am Coll Surg. 2022 Apr 1;234(4):579-588
pubmed: 35290278
Am J Transplant. 2021 May;21(5):1979-1980
pubmed: 33316117
Chin J Cancer Res. 2014 Feb;26(1):112-8
pubmed: 24653633
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Gut. 2005 Aug;54(8):1151-6
pubmed: 16009687
Indian J Med Res. 2017 Nov;146(Suppl):S30-S37
pubmed: 29578192
Gastroenterology. 2016 Dec;151(6):1155-1163.e2
pubmed: 27575820
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229
pubmed: 35065058
Ann Surg. 2020 Apr;271(4):616-624
pubmed: 30870180
Radiology. 2009 Sep;252(3):905-13
pubmed: 19567647
J Hepatol. 2009 Dec;51(6):1030-6
pubmed: 19864035
J Clin Oncol. 2013 Feb 1;31(4):426-32
pubmed: 23269991
Yonsei Med J. 2016 Sep;57(5):1276-81
pubmed: 27401662
Gastroenterology. 2004 Dec;127(6):1714-23
pubmed: 15578509
Scand J Gastroenterol. 2008;43(6):727-35
pubmed: 18569991
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Cell Physiol Biochem. 2018;48(5):1882-1893
pubmed: 30092590
Ann Surg Oncol. 2017 Jul;24(7):1843-1851
pubmed: 28160137
J Am Coll Surg. 2006 Oct;203(4):411-20
pubmed: 17000383
Transplant Direct. 2022 Mar 10;8(4):e1304
pubmed: 35310602
J Cancer Res Ther. 2016 Dec;12(Supplement):C148-C152
pubmed: 28230008
Radiology. 2002 May;223(2):331-7
pubmed: 11997534
Eur J Gastroenterol Hepatol. 2013 May;25(5):628-33
pubmed: 23325283
Hepatology. 2021 Jul;74(1):483-490
pubmed: 33369758
Gut. 2017 Jun;66(6):1172-1173
pubmed: 27884919
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218
pubmed: 35065057
Transpl Int. 2022 Oct 24;35:10915
pubmed: 36406781
J Hepatol. 2011 Oct;55(4):814-9
pubmed: 21334400